MOTS-c Rebound Effects When Stopping: What the Evidence Actually Shows

What 'rebound' would mean after a last MOTS-c dose

A rebound is a return that overshoots: a marker ends up worse than it was before treatment started. A fade is a return to the starting point. Telling them apart needs measurements taken in people after treatment stops.

MOTS-c can be measured in human blood as something the body makes on its own [6].

Has MOTS-c ever been given to a person?

For its July 2026 evaluation, FDA searched PubMed, Embase, the Cochrane library and other sources and found no clinical study in which MOTS-c, compounded or not, was given to humans; the 12 papers the nominator cited were not clinical studies [1]. Searches of FDA's adverse-event database through March 9, 2025 retrieved no MOTS-c reports [1].

The peptide is marketed on websites alone and in combinations, including an 'IV cocktail' offered by a wellness clinic, for metabolism, weight loss, glucose control, performance and anti-aging [1].

What the mouse data show

Lee et al. identified the 16-amino-acid peptide in 2015 and reported skeletal muscle as its main target, with AMPK activation through inhibition of the folate cycle [2]. In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity [2].

Later work reported about 20% lower body weight after 8 weeks at 0.5 mg/kg/day given intraperitoneally, improved insulin sensitivity and exercise performance, and a late-life schedule (15 mg/kg three times weekly from 23.5 months of age) that lengthened median lifespan from 912 to 970 days [1][3].

FDA says the molecular targets are unknown and no dose-response relationships were assessed. Rodent doses of 0.5 to 15 mg/kg cannot be converted into human doses [1].

Is there a human half-life to work from?

FDA found no pharmacokinetic data for MOTS-c in humans or in live animals [1]. The one kinetic observation is that MOTS-c breaks down quickly in human blood in vitro, which FDA said raises the question whether injecting it can produce active levels in people [1].

Without clearance data from people, how fast an injected dose would leave the body cannot be stated.

Regulatory status: not approved, and what the 2026 decisions mean

MOTS-c is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorised by the European Medicines Agency [1]. FDA's page on bulk substances that may raise significant safety risks when compounded lists MOTS-c in its 'nominated but withdrawn' table, for substances whose nominators withdrew them from category 2; removal from category 2 was not a finding that it is safe [10].

FDA staff recommended against adding it to the list of bulk substances that can be used in compounding, citing inconsistent naming and missing impurity, aggregate and endotoxin data, unknown use in compounding, no human safety or effectiveness data, no animal toxicity studies, and existing approved treatments for two of the nominated uses, obesity and osteoporosis [1].

The Pharmacy Compounding Advisory Committee voted in favour of adding it on July 23, 2026, against that recommendation. The vote is advice only, is not binding, and MOTS-c is not on the list; adding it would take formal rulemaking [7][8].

A separate HHS draft enforcement-discretion policy, filed October 28, 2026, names MOTS-c among six peptides and covers the acetate form given by subcutaneous or intramuscular injection. It says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound it under the policy's conditions, such as a single active ingredient and a patient-specific prescription [8][9]. The notice states that it establishes no rights, is not binding, and may be revisited, and that compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [8].

What is known about safety

FDA found no animal toxicity studies for MOTS-c, and its safety in humans is unknown [1]. FDA's stated concern for injectable peptides is immunogenicity, an immune reaction linked to aggregation and peptide-related impurities; MOTS-c has 16 amino acids and there are no immunogenicity data for it [1][10].

Sport status

WADA's Prohibited List names MOTS-c in section S4.4.1 among activators of AMP-activated protein kinase, prohibits it at all times in and out of competition, and classifies S4.4 substances as non-Specified Substances [5]. It is on the 2026 List, in force since January 1, 2026, and remains on the 2027 List [5][11].

Tapering, cycling and the body's own MOTS-c

There is no approved dose and no human dosing study; the nominated products were 5 mg and 10 mg subcutaneous injections [1]. With no human study of administered MOTS-c, none has compared tapering with stopping abruptly or tested repeated cycles.

Human research on MOTS-c has looked at the body's own peptide rather than injections. In a 2021 study in Nature Communications, exercise induced endogenous MOTS-c expression in skeletal muscle and in the circulation [3]. In a separate randomized trial, 30 healthy adults did 45 minutes of endurance cycling (n=10), resistance exercise (n=10) or nothing (n=10); circulating MOTS-c showed only a trend to increase after endurance exercise, and plasma levels were not related to fitness [6]. Participants in these studies were not given MOTS-c [3][6].

Bottom line

The metabolic findings usually cited are mouse results. What an injected course does in a person, and what follows a last dose, have not been described [1][2][3].